MaxCyte, Inc.
MXCTNASDAQHealthcare● Active
$1.16
+$0.02(+1.75%)
Market Cap$124261140
P/E Ratio—
52W High$2.4
52W Low$0.643
MaxCyte, Inc. (MXCT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MXCT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $33.03M | $38.63M | $41.29M | $44.26M | $33.89M |
| Cost of Revenue | $6.22M | $7.10M | $4.74M | $5.10M | $3.65M |
| Gross Profit | $26.80M | $31.53M | $36.55M | $39.16M | $30.25M |
| Gross Margin %(computed) | 81.16% | 81.62% | 88.51% | 88.48% | 89.24% |
| Operating Expenses | |||||
| R&D Expenses | $20.82M | $22.23M | $23.82M | $19.51M | $15.41M |
| G&A Expenses | $28.12M | $29.69M | $30.07M | $25.83M | $18.68M |
| Total Operating Expenses | $72.09M | $82.72M | $84.84M | $66.52M | $48.44M |
| Operating Income | ($45.28M) | ($51.20M) | ($48.30M) | ($27.36M) | ($18.19M) |
| Operating Margin %(computed) | -137.12% | -132.54% | -116.98% | -61.82% | -53.66% |
| Interest Income | $7.27M | $10.14M | $10.38M | $3.92M | $0.15M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.13M | $1.04M |
| Income Before Tax | ($44.63M) | ($41.05M) | ($37.92M) | ($23.57M) | ($19.08M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($44.63M) | ($41.05M) | ($37.92M) | ($23.57M) | ($19.08M) |
| Net Margin %(computed) | -135.14% | -106.29% | -91.85% | -53.25% | -56.30% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.42 | $-0.39 | $-0.37 | $-0.19 | $-0.22 |
| Wtd Avg Shares | 106.43M | 104.85M | 103.27M | 101.70M | 90.62M |
| EBITDA | ($40.14M) | ($46.41M) | ($44.13M) | ($24.66M) | ($16.61M) |
| EBITDA Margin %(computed) | -121.55% | -120.14% | -106.88% | -55.72% | -49.02% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more MaxCyte, Inc. data
About MaxCyte, Inc. (MXCT) Income Statement
MaxCyte, Inc. (MXCT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, MXCT reported revenue of $0.03B, gross profit of $0.03B (gross margin 81.16%), and net income of ($0.04B) — a net profit margin of -135.14%.
Frequently asked questions
MXCT · 4 questionsMaxCyte, Inc. (MXCT) reported revenue of $0.03B for 2025, down 14.5% year-over-year.
MXCT revenueMXCT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08